N
N

Novartis

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Novartis halts study of iscalimab in kidney transplant patients

ZURICH, Sept 3 (Reuters) - Novartis NOVN.S has halted a clinical trial of CFZ533 (iscalimab) in kidney transplant patients after interim data showed it was not as good as tacrolimus-based treatment in preventing organ rejection, the Swiss group said on Friday. Its study of the medicine in liver transplant continues, as do studies exploring it as a
N

Blue-chip earnings, travel stocks boost European shares

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window) * ASML nears record high after results * STOXX 600 Q2 profit seen rising 115% * SAP slips despite forecast lift (Updates to close) By Sruthi Shankar July 21 (Reuters) - A slew of upbeat updates from European blue-chip firms helped the region
N
S
A
G
E
F
U

Novartis weighs entry into mRNA technology, chairman tells paper

ZURICH, July 1 (Reuters) - Swiss drugmaker Novartis NOVN.S could get into the field of messenger ribonucleic acid (mRNA) technology, which has come to the fore in vaccine development during the coronavirus pandemic, Chairman Joerg Reinhardt said in a newspaper interview. In the Aargauer Zeitung interview, Reinhardt also highlighted the company's re
N

Novartis weighs entry into mRNA technology -chairman tells paper

ZURICH, July 1 (Reuters) - Swiss drugmaker Novartis NOVN.S could get into the hot field of messenger ribonucleic acid (mRNA) technology, which has come to the fore during the coronavirus pandemic, Chairman Joerg Reinhardt said in a newspaper interview. "The mRNA technology has proven to be an attractive option in this situation and of course every
N

CureVac 19 vaccine records only 48% efficacy in final trial readout

By Ludwig Burger June 30 (Reuters) - CureVac 5CV.DE said its COVID-19 vaccine was 48% effective in the final analysis of its pivotal mass trial, only marginally better than the 47% reported after an initial read-out two weeks ago. The German biotech firm said that efficacy, measured by preventing symptomatic disease, was slightly better at 53% when
B
G
N
P

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.